Stifel Reiterates Buy Rating on Biogen (BIIB)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Stifel Reiterates Buy Rating on Biogen (BIIB)
June 7, 2024 9:14 AM EDT
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $317.00 price target on Biogen (NASDAQ: BIIB)
The analyst comments "This morning, Symphony reported $9.9M in May sales for Leqembi, up 18% from April's $8.3M in monthly sales, suggesting to us that Leqembi sales continue to move in the right direction. As we closely follow Leqembi metrics across two third-party prescription... More
June 6, 2024 9:50 AM EDT
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $317.00 price target on Biogen (NASDAQ: BIIB)
The analyst comments "Based on the briefing documents, in the end we would expect both BIIB's and LLY's Alzheimer's antibodies to be on the market, believe LLY... More
June 5, 2024 6:11 AM EDT
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $317.00 price target on Biogen (NASDAQ: BIIB).
The analyst comments "With Leqembi use growing but not yet inflecting, we believe the Street is looking for catalysts to further energize NT uptake. With briefing docs... More
